Novel <sup>68</sup>Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine-Related Pitfalls.
Where this comes from
- Record sourced from PubMed, PMID 36396454.
- Also identified by DOI 10.2967/jnumed.122.264872 and PMC identifier 10071804.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
In the setting of ongoing coronavirus disease 2019 vaccination, vaccine-related tracer uptake in locoregional lymph nodes has become a well-known issue in tumor staging by <sup>18</sup>F-FDG PET/CT. <sup>68</sup>Ga-fibroblast-activation protein inhibitor (FAPI) PET/CT is a new oncologic imaging tool that may overcome this limitation. <b>Methods:</b> We assessed postvaccine head-to-head and same-day <sup>18</sup>F-FDG and <sup>68</sup>Ga-FAPI-46 PET/CT findings in a series of 11 patients from a large, prospective imaging registry. All patients with documented tracer uptake in locoregional lymph nodes on PET/CT or PET/MRI, after vaccination within 6 wk, were eligible for investigation. <b>Result:</b> Significant visual lymph node uptake adjacent to the injection site was noted in 11 of 11 (100%) patients with <sup>18</sup>F-FDG PET/CT, versus 0 of 11 (0%) with <sup>68</sup>Ga-FAPI PET/CT. <sup>18</sup>F-FDG detected 73% and <sup>68</sup>Ga-FAPI PET/CT 94% of all tumor lesions. <b>Conclusion:</b> In this case-series study, <sup>68</sup>Ga-FAPI showed its potential to avoid <sup>18</sup>F-FDG PET/CT postvaccination pitfalls and presented superior tumor localization.
Medical subject headings
- Neoplasm Staging
- Lymph Nodes
- Neoplasms